ABCA1 and Cognitive impairment: Treatment with the ABCA1 agonist CS-6253 which reverses the brain pathological effects of apoE4 and the associated cognitive impairments [25], reverses the effects of apoE4 on the lipidation and aggregation of plasma apoE4 without affecting the total corresponding apoE3 levels.